Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

JY, Blay; C, Serrano; MC, Heinrich; J, Zalcberg; S, Bauer; H, Gelderblom; P, Schöffski; RL, Jones; S, Attia; G, D'Amato; P, Chi; P, Reichardt; J, Meade; K, Shi; R, Ruiz-Soto; S, George; Mehren M, von

doi:10.1016/s1470-2045(20)30168-6

Public

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Shared by NobleBlocks on Jun 5, 2020 • 12:00 AM UTC

Authors:

Blay JY

Serrano C

Heinrich MC

Abstract

Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!